BLUE-CLOUD-VENTURES
Blue Cloud Management LLC (“Blue Cloud Ventures” or “BCV”), a leading venture capital firm headquartered in New York City, is proud to announce the opening of its European office in Berlin. Blue Cloud Ventures is a growth-stage VC focused on B2B SaaS companies globally. BCV has invested in 43 companies to date, including investments in European companies such as Cognism, Templafy, and most recently, LMS365.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230426005089/en/
Blue Cloud Ventures Team (Photo: Business Wire)
With the European tech scene experiencing rapid growth over the past few years, BCV is keen to be part of this emerging ecosystem and partner with founders and investors in the region.
The office will be headed by Victor Yaw, who has been involved in BCV's investments such as Paradox, Trulioo, and Go1, as well as Cognism, Templafy, and LMS365 in Europe.
“We’re thrilled that Victor will be leading our efforts to expand our global footprint; we have been deepening our presence across various regions since raising our fourth fund and see a surge in high-quality B2B SaaS companies being built in Europe,” said Rami Rahal, co-founder and Managing Partner of BCV.
Leveraging its deep U.S. roots, its LP network of 100+ technologists and entrepreneurs globally, and connections across equity and debt funds and service providers, BCV aims to bring a unique set of value-add to European B2B SaaS companies. Through its European presence, BCV will also work closely with its existing portfolio companies in the region, supporting them on their growth journey.
“Since our founding, we have remained focused on being the best partners to our entrepreneurs and their teams,” said Mir Arif, co-founder and Managing Partner of BCV. “We are proud of our readiness to roll up our sleeves and add value, whether by acting as a sounding board to founders, or by assisting with strategy, M&A, recruiting, or customer introductions.”
Berlin was a natural choice for BCV's expansion into Europe, given its status as a tech hub for the region, its location at the heart of the Europe, and its connectivity with other major European cities. The city has a supportive ecosystem for early-stage startups and is quickly emerging as a major hub for companies looking to scale to multi-billion outcomes.
“We are at a key inflection point for B2B SaaS in Europe," said Victor Yaw. "We’ve seen the emergence of a next generation of company builders that have developed the expertise to truly scale to become category-defining platforms. We are excited about our existing investments in the region and believe that this is just the tip of the iceberg."
About Blue Cloud Ventures
Blue Cloud Ventures (BCV) is a software-focused growth stage venture capital fund firm headquartered in New York City. The fund targets investments in leading business applications, infrastructure and open-source software companies. Some of BCV’s past and present portfolio companies include Arctic Wolf Networks, Clari, Cloudbees, Druva, Go1, Iterable, NGINX, Templafy, Pax8 and Wrike. For more information on BCV and our portfolio companies, please visit www.bluecloudventures.com.
Disclaimer - Nothing presented within this article is intended to constitute investment advice, and under no circumstances should any information provided herein be used or considered as an offer to sell or a solicitation of an offer to buy an interest in any investment fund managed by Blue Cloud Management LLC (“Blue Cloud Ventures”). Blue Cloud Ventures does not provide investment advice and is not registered in Germany. Information provided reflects Blue Cloud Ventures’ views as of a time, whereby such views are subject to change at any point and Blue Cloud Ventures shall not be obligated to provide notice of any change. Nothing contained in this article may be relied upon as a guarantee or assurance as to the future success of any particular company. Companies mentioned in this article are a representative sample of portfolio companies in which Blue Cloud Ventures has invested in which the author believes such companies fit the objective criteria stated in commentary, which do not reflect all investments made by Blue Cloud Ventures. Blue Cloud Ventures does not solicit or make its services available to the public and none of the funds are currently open to new investors. While Blue Cloud Ventures has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability, or completeness of third-party information presented herein, which is subject to change. Past performance is not indicative of future results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005089/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AwardFares Launches Intelligent New Alert System for Award Flight Availability5.8.2025 08:00:00 CEST | Press release
AwardFares, the leading search platform for award flights, today launched a major upgrade to its alert system, giving users smarter tools to discover and book award availability faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804412041/en/ AwardFares' Timeline view provides a clear, color-coded visualization of daily award seat availability across different cabin classes, helping users easily spot trends and opportunities for flights. The new system includes two powerful features: Flex Alerts and Live Alerts. Together, they provide both flexibility and precision, helping travelers maximize their points and miles like never before. Flex Alerts are designed for the flexible traveler. Instead of requiring an exact route and date, users can set broad criteria such as "any airport in the US to Europe for an entire month.” AwardFares' AI-powered system intelligently identifies matching availability, focusing not just on
Venture Global Calcasieu Pass Receives Uprate Approval from U.S. Department of Energy5.8.2025 02:02:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) received approval from the U.S. Department of Energy (DOE) for an uprate amendment to its Calcasieu Pass LNG project. The uprate approval increases Calcasieu Pass’ permitted peak liquefaction capacity from 12.0 million tonnes per annum (MTPA) to 12.4 MTPA. “Venture Global thanks its regulators, including DOE, for their efforts in prioritizing and streamlining approvals for critical energy infrastructure projects. These multibillion dollar investments will be key as the United States strengthens global energy security and increases energy trade with our partners around the world,” said Venture Global CEO Mike Sabel. Calcasieu Pass, Venture Global’s first project, reached first LNG production in 2022 and began commercial operations in April 2025. The company’s second facility, Plaquemines LNG, began LNG production in December 2024. Venture Global’s third project, CP2, received DOE export authorization and FERC approval in March 2025 and May 2025, re
Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain4.8.2025 22:01:00 CEST | Press release
– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint –– Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo. VX-993 was generally safe and well tolerated. Most adverse events (AEs) were mild to moderate, and there were no serious adverse events (SAEs) related to VX-993. Based on these results, Vertex will not progress
TOURISE Announces Cross-Sector Advisory Board to Champion Bold New Platform Rewriting the Rules of Tourism4.8.2025 20:53:00 CEST | Press release
Leaders from World Travel & Tourism Council (WTTC), Global Sustainable Tourism Council, Amadeus, TikTok, Six Senses, Cirque du Soleil, Turismede Barcelona, Liberty International, Wagonlit Travel, Once Billion Happy, the Saudi Tourism Authority (STA), and the Riyadh School of Tourism and Hospitality at the helm of TOURISE Advisory Board Formation of the Advisory Board reinforces TOURISE’s dedication to driving cross-sector global collaboration Advisory Board shape TOURISE summit agenda, ensuring high-impact global issues such as equity, geographical representation and sectoral diversity are in spotlight TOURISE, the bold new global tourism platform, has announced the members of its cross-sector Advisory Board, a powerhouse of industry titans guiding TOURISE’s strategic direction and shaping the agenda of the inaugural global summit taking place in Riyadh from 11-13 November, 2025. TOURISE is where cross-sector convergence begins, a platform where leaders and visionaries debate, collabor
Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe4.8.2025 20:38:00 CEST | Press release
Concept Medical Inc., a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA’s IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical’s mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804524652/en/ Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Study Dr. Samin Sharma enrolled the first patient at New York’s Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom